XXXX for @entity11 : predictive impact of 1p/19q loss on response and outcome.

@entity1 @entity5 @entity11 @entity2903 @entity2904
OBJECTIVE: To evaluate the predictive impact of chromosome 1p/19q deletions on the response and outcome of progressive @entity11 ( @entity11 ) treated with up-front @entity2903 ( @entity2904 ) chemotherapy. METHODS: Adult @entity1 with measurable, progressive @entity11 (WHO grade II) treated with @entity2904 delivered at the conventional schedule (200 mg/m(2)/day for 5 consecutive days, repeated every 28 days) were retrospectively evaluated for response by central review of MRI-s. Chromosome 1p and 19q deletions were detected by the loss of the heterozygosity technique (LOH). RESULTS: A total of 149 consecutive @entity1 were included in this retrospective, single center observational study. The median number of @entity2904 cycles delivered was 14 (range 2 to 30). Seventy-seven @entity1 (53%) experienced an objective response (including 22 [15%] cases of partial response and 55 [38%] cases of minor response), 55 (37%) @entity1 had stable disease, and 14 (10%) had a progressive disease. The median time to maximum @entity5 response was 12 months (range 3 to 30 months). The median progression-free survival (PFS) was 28 months (95% CI: 23.4 to 32.6). Material for genotyping was available for 86 @entity1 . Combined 1p/19q LOH was present in 42% of the cases and was significantly associated with a higher rate (p = 0.02) and longer objective response to chemotherapy (p = 0.017), and both longer PFS (p = 4.10(-5)) and overall survival (p = 0.04). CONCLUSION: Low-grade @entity11 respond to @entity2903 and loss of chromosome 1p/19q predicts both a durable chemosensitivity and a favorable outcome.
